Pharmacokinetic and pharmacodynamic aspects of an ophthalmic pilocarpine nanoparticle-delivery-system.
The regional pharmacokinetics as well as the pharmacodynamics of pilocarpine-loaded nanoparticles for the treatment of glaucoma were investigated and compared to a solution of this drug. Polybutylcyanoacrylate nanoparticles were prepared by an emulsion polymerization process. Formulations with different drug concentrations (2-6%) as well as different particle concentrations were investigated and analyzed for size and drug loading. Drug binding to the particles was achieved at a level of 10-18% of the total drug content. The colloidal nanoparticles were sufficiently small (diameter: 100-300 nm) for a non-irritating application to the eye. All preparations were applied to the eyes of New Zealand white rabbits which were treated with betamethasone before to create an elevated intraocular pressure (IOP). Pilocarpine concentrations, assayed from aqueous humor using gaschromatography, increased by 23% (AUC) for nanoparticle suspensions compared to aqueous reference solutions. Additionally, t1/2 was prolonged and the elimination coefficient was significantly decreased. Pharmacodynamic effects such as miosis and IOP reduction were investigated. tmax values of aqueous humor concentration were observed to be in a similar time range as miosis tmax readings. It was found that at lower drug contents a more pronounced prolongation of miosis was achieved with nanoparticles versus a standard solution. The IOP-reduction was significantly prolonged with nanoparticles preparations; whereas maximum reduction was obtained with a reference solution after 1-2 hours, it was reached with nanoparticles at about 2-3 hours. Differences between nanoparticles and aqueous solutions were most pronounced at lower drug concentrations.
Institut für Pharmazeutische Technologie, Biozentrum Niederursel Universität Frankfurt a.M., Germany.
A
A
Zimmer
E
E
Mutschler
G
G
Lambrecht
D
D
Mayer
J
J
Kreuter
D000818:Animals; D001082:Aqueous Humor / Q000378:metabolism; D001623:Betamethasone; D002849:Chromatography, Gas; D005901:Glaucoma / Q000188:drug therapy; D006207:Half-Life; D007429:Intraocular Pressure / Q000187:drug effects; D008863:Microspheres; D009883:Ophthalmic Solutions; D010316:Particle Size; D010862:Pilocarpine / Q000008:administration & dosage* / Q000493:pharmacokinetics* / Q000494:pharmacology; D011817:Rabbits
D009883:Ophthalmic Solutions; D010862:Pilocarpine; D001623:Betamethasone